These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24614714)

  • 21. [New Croatian legislation on tissue banking].
    Busić M
    Acta Med Croatica; 2007 Dec; 61(5):445-7. PubMed ID: 18350803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Material & equipment, procurement & maintenance: Impact on blood safety.
    Emmanuel JC
    Biologicals; 2010 Jan; 38(1):78-80. PubMed ID: 20079663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Blood transfusion: the challenges for tomorrow?].
    Folléa G; Garraud O; Tiberghien P
    Presse Med; 2015 Feb; 44(2):227-32. PubMed ID: 25578549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tools for improving quality in the transfusion service.
    Berte LM
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S36-42. PubMed ID: 9124228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory issues in cell-based therapy for clinical purposes.
    Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
    Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transposing the E. E. U. Blood Directive into national law. Perspective of Slovenia.
    Potocnik M
    Transfus Clin Biol; 2005 Feb; 12(1):21-4. PubMed ID: 15814288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical issues in tissue banking.
    Haimowitz MD
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S75-81. PubMed ID: 9124234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.
    Galbraith DN
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):35-9. PubMed ID: 15270705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B
    Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue banking in australia.
    Ireland L; McKelvie H
    Cell Tissue Bank; 2003; 4(2-4):151-6. PubMed ID: 15256853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. PLUS.
    Mahony BO; Turner A
    Vox Sang; 2010 Apr; 98(3 Pt 2):447-50. PubMed ID: 20158697
    [No Abstract]   [Full Text] [Related]  

  • 36. European regulations and their impact on tissue banking.
    Tatarenko A
    Cell Tissue Bank; 2006; 7(4):231-5. PubMed ID: 16821111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. National control requirements for blood products in Australia.
    Graham DT
    Dev Biol Stand; 1987; 67():229-32. PubMed ID: 3609479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience.
    Balcerek J; Shy BR; Putnam AL; Masiello LM; Lares A; Dekovic F; Acevedo L; Lee MR; Nguyen V; Liu W; Paruthiyil S; Xu J; Leinbach AS; Bluestone JA; Tang Q; Esensten JH
    Front Immunol; 2021; 12():744763. PubMed ID: 34867967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Will regulation be the death of cell therapy in the United States?
    Gastineau DA
    Bone Marrow Transplant; 2004 Apr; 33(8):777-80. PubMed ID: 14968138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.